Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B.

Published on Aug 15, 2019in Gut and Liver2.968
· DOI :10.5009/gnl18474
Young Youn Cho9
Estimated H-index: 9
(CAU: Chung-Ang University),
Young Jun Chang21
Estimated H-index: 21
(SNU: Seoul National University)
+ 6 AuthorsYoon Jun Kim37
Estimated H-index: 37
(SNU: Seoul National University)
  • References (0)
  • Citations (0)
📖 Papers frequently viewed together
17 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Di Wu (HUST: Huazhong University of Science and Technology)H-Index: 1
#2Qin Ning (HUST: Huazhong University of Science and Technology)H-Index: 1
Chronic hepatitis B virus (HBV) infection remains a major global health burden. Currently, the approved therapeutic regimens include nucleos(t)ide analogues (NAs) and either interferon or pegylated interferon. NA therapy is generally safe and well tolerated, but the rate of posttreatment virologic relapse is high, making NA treatment a lifetime commitment. The benefits of pegylated interferon treatment include a finite duration, more-durable response and absence of viral resistance. However, sus...
10 CitationsSource
#1Eun Ju Cho (SNU: Seoul National University)H-Index: 16
#2Sung Eun Kim (Sacred Heart Hospital)H-Index: 6
Last. Yoon Jun Kim (SNU: Seoul National University)H-Index: 37
view all 7 authors...
19 CitationsSource
#1Syed Abdul Basit (UNR: University of Nevada, Reno)H-Index: 2
#2Altaf Dawood (UNR: University of Nevada, Reno)H-Index: 1
Last. Robert G. Gish (UNR: University of Nevada, Reno)H-Index: 57
view all 4 authors...
ABSTRACTIntroduction: In April 2017 tenofovir alafenamide (TAF) was added to the list of first-line therapies recommended for chronic hepatitis B (CHB). TAF has pharmacology similar to tenofovir disoproxil fumarate (TDF) with higher cell delivery to the hepatocytes but less systemic exposure.Areas covered: We review here studies leading to TAF’s approval and comparing it to TDF. In two major clinical trials, TAF was non-inferior to TDF in achieving HBV DNA levels below 29 IU/ml. TAF-treated pati...
6 CitationsSource
#1Mar Riveiro-Barciela (Autonomous University of Barcelona)H-Index: 10
#2David Tabernero (Autonomous University of Barcelona)H-Index: 12
Last. Maria Buti (Autonomous University of Barcelona)H-Index: 61
view all 23 authors...
Background Long-term antiviral therapy has resulted in viral suppression and biochemical response in chronic hepatitis B, although the risk of hepatocellular carcinoma has not been abolished. The Page-B score could be useful to estimate the probability of HCC.
12 CitationsSource
#1Hyeki Cho (SNU: Seoul National University)H-Index: 7
#2Yuri Cho (SNU: Seoul National University)H-Index: 14
Last. Yoon Jun Kim (SNU: Seoul National University)H-Index: 37
view all 10 authors...
Tenofovir disoproxil fumarate (TDF) is effective against chronic hepatitis B (CHB) infection and its use is increasing rapidly worldwide. However, it has been established that TDF is associated with renal toxicity in human immunodeficiency virus-infected patients, while severe or symptomatic TDF-associated nephrotoxicity has rarely been reported in patients with CHB. Here we present two patients with TDF-associated nephrotoxicity who were being treated for CHB infection. The first patient was fo...
3 CitationsSource
#1Anna S.F. Lok (UM: University of Michigan)H-Index: 44
#2Brian J. McMahon (Alaska Native Tribal Health Consortium)H-Index: 58
Last. Khaled MohammedH-Index: 21
view all 17 authors...
Chronic hepatitis B viral (HBV) infection remains a significant global health problem. Evidence-based guidelines are needed to help providers determine when treatment should be initiated, which medication is most appropriate, and when treatment can safely be stopped. The American Association for the Study of Liver Diseases HBV guideline methodology and writing committees developed a protocol a priori for this systematic review. We searched multiple databases for randomized controlled trials and ...
148 CitationsSource
#1M.-C. Tsai (CGU: Chang Gung University)H-Index: 2
#2Chyi-Liang Chen (Memorial Hospital of South Bend)H-Index: 14
Last. Tsung-Hui Hu (Memorial Hospital of South Bend)H-Index: 32
view all 13 authors...
Abstract This study aims to assess the nephrotoxicity and efficacy of tenofovir disoproxil fumarate (tenofovir), telbivudine and entecavir. A retrospective study of 587 patients with chronic hepatitis B treated with tenofovir ( n = 170), telbivudine ( n = 184) and entecavir ( n = 233) for at least 1 year. Renal function and efficacy were assessed. The estimated glomerular filtration rate (eGFR) decreased significantly in the tenofovir group after a mean of 17 months treatment (from 92.2 to 85.6 ...
23 CitationsSource
#1Norah A. Terrault (UCSF: University of California, San Francisco)H-Index: 67
#2Natalie Bzowej (Ochsner Medical Center)H-Index: 28
Last. M. Hassan Murad (Mayo Clinic)H-Index: 94
view all 6 authors...
Aasld Guidelines for Treatment of Chronic Hepatitis B Norah Terrault;Natalie Bzowej;Kyong-Mi Chang;Jessica Hwang;Maureen Jonas;Hassan Murad; Hepatology
767 CitationsSource
#1Hyeon Seok Hwang (CUA: The Catholic University of America)H-Index: 1
#2Cheol Whee Park (CUA: The Catholic University of America)H-Index: 1
Last. Myeong Jun Song (CUA: The Catholic University of America)H-Index: 2
view all 3 authors...
Tenofovir disoproxil fumarate (TDF) is widely used as an effective first-line therapy for chronic hepatitis B (CHB) infection. While TDF demonstrates successful viral suppression, it has been linked to the development of renal proximal tubular (PT) dysfunction, leading to Fanconi syndrome. However, Fanconi syndrome has been rarely reported in CHB-monoinfected patients, and there were no reports of TDF-associated nephrotic syndrome. Here, we report a case of combined Fanconi and nephrotic syndrom...
16 CitationsSource
#1Seyfettin Köklü (Hacettepe University)H-Index: 20
#2Murat Taner GulsenH-Index: 6
Last. Erhan AlkanH-Index: 3
view all 25 authors...
SummaryBackground Results are conflicting with respect to the renal effects of anti-viral agents used for hepatitis B virus infection. Aim To compare short and long-term renal effects in real-life settings and to determine risk factors for renal impairment during treatment. Methods 2221 treatment-naive patients were enrolled. Among these, 895 (302 lamivudine, 27 telbivudine, 282 entecavir, 273 tenofovir and 11 adefovir initiated patients) had ‘repeated measures’ of creatinine (baseline, 1st, 6th...
23 CitationsSource
Cited By0